Amniotic eye drops are a topical treatment derived from human amniotic membrane or amniotic fluid, and they are used primarily for severe dry eye, non-healing corneal wounds, and other stubborn ocular surface diseases that have stopped responding to conventional therapy. The tissue contains a cocktail of growth factors, anti-inflammatory proteins, and collagen that can help a damaged corneal surface repair itself. Clinical interest has grown quickly since the first ophthalmic use of amniotic tissue in the 1940s, but the science, the regulation, and the marketing have not always moved at the same pace, which makes the topic worth unpacking carefully.
Why Amniotic Tissue Helps Eyes Heal
The amniotic membrane is the innermost layer of the placenta, and it turns out to be remarkably well-suited for eye repair. It contains organized collagen, anti-fibrotic and anti-inflammatory signaling molecules, immune-modulators, growth factors, and matrix proteins that together promote healing in severely damaged corneas.1PubMed Central. Amniotic membrane extract and eye drops: a review of literature and clinical application In practical terms, the membrane supplies many of the same signals your corneal cells need to rebuild after an injury, but packaged in a form your eye can absorb.
One key mechanism involves dampening scar formation. The extract appears to keep fibroblasts from converting into the type of cells that lay down scar tissue, which helps preserve corneal clarity during healing.2PubMed Central. Amniotic Membrane Extract Eye Drop Promotes Limbal Stem Cell Proliferation and Corneal Epithelium Healing Scarring on the cornea is a major problem after burns, infections, and surgical trauma because even a small opaque patch directly in the line of sight can blur vision permanently. By reducing that scarring response while still promoting new epithelial growth, amniotic drops address two problems at once.
The extract also supports the limbal stem cells that sit at the border of the cornea and the white of the eye. These stem cells continuously replenish the corneal surface, and when they are depleted or damaged, the surface breaks down. Research suggests amniotic membrane extract promotes the proliferation of these stem cells, which is partly why the drops are useful in conditions where the limbal cell population has been wiped out.2PubMed Central. Amniotic Membrane Extract Eye Drop Promotes Limbal Stem Cell Proliferation and Corneal Epithelium Healing
Conditions Where Amniotic Eye Drops Are Used
These drops are not a first-line treatment for run-of-the-mill dry eye. They tend to be reserved for cases that have failed conventional options like artificial tears, anti-inflammatory drops, and punctal plugs. The conditions most commonly treated include severe dry eye disease, persistent epithelial defects (wounds on the corneal surface that refuse to close), limbal stem cell deficiency, neurotrophic ulcers, and ocular surface damage from autoimmune diseases like Sjögren’s syndrome or graft-versus-host disease (GVHD).
A study evaluating amniotic membrane eye drops across multiple refractory conditions found measurable improvements in corneal surface grading for patients with GVHD and limbal stem cell deficiency, along with improvements in conjunctival grading across GVHD, limbal stem cell deficiency, Sjögren’s syndrome, and non-Sjögren’s dry eye. Tear film stability improved in nearly all groups.3PubMed. Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations The breadth of conditions that responded is notable, though the researchers also observed that patient-reported symptom scores showed only modest changes in some groups. That gap between what the doctor sees under the slit lamp and what the patient feels at home comes up repeatedly in this literature.
Chemical burns represent another important use. The amniotic membrane has a long track record in treating chemical injury to the eye, and its extract form allows ongoing topical dosing after the acute phase, when transplanting a membrane sheet may no longer be practical.1PubMed Central. Amniotic membrane extract and eye drops: a review of literature and clinical application
Evidence for Corneal Wound Healing
The most striking results show up in patients with persistent epithelial defects, which are corneal wounds that remain open for weeks despite standard care. In a study of 16 patients with these stubborn wounds, two months of amniotic membrane extract eye drops shrank the average defect area from about 5.2 mm² down to essentially zero. Visual acuity improved as well, and pain scores dropped. Treatment was considered effective in about 80% of patients and partially effective in the rest.4Journal of the Korean Ophthalmological Society. Effects of Amniotic Membrane Extract Eye Drops on Persistent Epithelial Defects of the Cornea For wounds that have resisted everything else, those are encouraging numbers.
A separate prospective study in patients with severe ocular surface disease, including chronic dry eye, limbal stem cell deficiency, and neurotrophic ulcers, found that at least four weeks of amniotic membrane extract eye drops led to significant improvements in symptoms like foreign body sensation, itching, and stinging. Every patient with a corneal ulcer achieved complete re-epithelialization, meaning the wound surface closed entirely.5PubMed. Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies The visual quality function questionnaire did not reach statistical significance in that study, which hints again at the pattern of objective healing outpacing the patient’s subjective sense of improvement.
Dry Eye and Tear Film Stability
For dry eye specifically, the evidence centers on tear film stability. A prospective cohort study measuring tear break-up time, the standard clinical test for how long your tear film stays intact between blinks, found that lyophilized amniotic membrane eye drops nearly doubled it. Average tear break-up time rose from about 7 seconds at baseline to around 12 seconds by the end of treatment. Corneal and conjunctival staining scores, which reflect surface damage, both dropped significantly as well.6PubMed Central. Lyophilized Amniotic Membrane Eye Drops Stabilize the Tear Film in Dry Eye Disease: A Prospective Cohort Study A tear break-up time below 10 seconds is generally considered abnormal, so moving from 7 to 12 represents a clinically meaningful shift out of the danger zone.
A separate trial using amniotic cytokine extract in dry eye patients found significant improvements in corneal staining, conjunctival staining, visual acuity, and symptom scores at four weeks, with continued improvement out to twelve weeks of follow-up.7PubMed Central. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease That sustained benefit beyond the treatment period is interesting because it suggests the drops may trigger some degree of lasting surface repair, not just temporary lubrication.
How They Compare to Other Treatments
Autologous serum eye drops, made from a patient’s own blood, have been the go-to biologic drop for severe ocular surface disease for years. In a rabbit model of alkaline corneal injury, amniotic membrane suspension healed epithelial wounds faster than both autologous serum and preservative-free artificial tears.8Cornea. Comparison of the Effect of Amniotic Membrane Suspension and Autologous Serum on Alkaline Corneal Epithelial Wound Healing in the Rabbit Model Animal models do not always translate perfectly to human outcomes, but this comparison matters because autologous serum drops require a blood draw from the patient, processing, and cold storage, while amniotic drops can be manufactured from donor tissue in standardized batches.
Compared to amniotic membrane transplantation, where a sheet of membrane is physically sutured or glued onto the eye surface, the drop formulation has the obvious advantage of being non-invasive. Preclinical models have suggested better outcomes with the extract compared to transplanted membrane.9Academic Medicine & Surgery. Comment on: The Healing Power of Amniotic Membrane Extract Eye Drops The likely reason is dosing flexibility. A transplanted membrane delivers its contents once and then dissolves. Eye drops can be applied repeatedly over weeks, allowing a sustained delivery of growth factors that a single membrane placement cannot match. One preclinical study specifically designed its dosing protocol so that each day’s drops delivered roughly the same protein content as a single transplanted membrane, applied four times daily.10PubMed Central. Clinically correlated dose of the amniotic membrane extract is superior to its transplantation in corneal wound healing
Cryopreserved amniotic membrane placement, where a patch of membrane is laid over the eye and allowed to dissolve in place, sits somewhere in between. A small case series of Sjögren’s syndrome patients treated with self-retained cryopreserved membrane found reduced corneal and conjunctival staining in most eyes, but the effects were temporary.11PubMed Central. The use of self-retained, cryopreserved amniotic membrane for the treatment of Sjögren syndrome: a case series That finding reinforces the appeal of a drop formulation, which can be continued for as long as the patient needs it.
Safety Profile
The safety data, while still limited to relatively small studies, has been consistently reassuring. In the prospective trial of patients with severe ocular surface disease, topical amniotic membrane extract eye drops were described as safe and well tolerated, with no serious adverse events reported.5PubMed. Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies A pilot study of amniotic fluid in severe dry eye found no cases of inflammation, infection, irritation, or blurred vision across the treated patients.12PubMed Central. A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease
That said, there are inherent risks with any product derived from human tissue. Donor screening and sterility protocols are critical. The tissue comes from screened donors, typically women undergoing planned cesarean deliveries, and reputable processing centers follow tissue-banking standards to minimize infection risk. But because many of these products occupy a regulatory gray area, as discussed below, quality control can vary significantly between providers.
How They Are Made
Making amniotic eye drops is not as simple as blending a membrane and bottling it. The preparation process matters enormously because it determines which growth factors survive and in what concentrations. Generally, the amniotic membrane is cleaned, processed into an extract or homogenate, and then either frozen for storage or freeze-dried (lyophilized) into a powder that is reconstituted before use.
Lyophilization has become increasingly popular because it simplifies storage and extends shelf life. Research has shown that lyophilized amniotic membrane sterilized with supercritical carbon dioxide maintains biochemical properties and biocompatibility comparable to products requiring specialized cold storage.13PubMed. Amniotic membrane allografts maintain key biological properties post SCCO(2) and lyophilization processing This matters for practical access because cold-chain distribution limits where products can go, while a shelf-stable powder can be shipped and stored much more easily.
The specific extraction protocol also affects what ends up in the final product. Recent research has confirmed that factors like the extraction buffer, the use of protease inhibitors, and cryo-milling techniques all influence how much of each growth factor is recovered from the tissue. Standardizing these variables is an ongoing challenge, but the field is moving toward systematic optimization so that different batches deliver consistent potency.14Springer Link / Cell Tissue Bank. Determinants of extraction efficiency in human amniotic membrane processing: biological, mechanical, and biochemical factors shaping growth factor yield For now, “amniotic eye drops” from one company or eye bank may not contain the same growth factor profile as those from another.
The Regulatory Landscape in the United States
This is where things get complicated, and where patients need to pay the most attention. In the U.S., amniotic membrane products used as tissue grafts are regulated by the FDA as human cells, tissues, and cellular and tissue-based products (HCT/Ps), which have a relatively streamlined regulatory pathway as long as the tissue is minimally processed and used for homologous purposes. But amniotic fluid products do not fall under this same classification. The FDA does not regard amniotic fluid as an HCT/P, and to date, no amniotic fluid-based eye drops have received FDA approval in the United States.15PubMed Central. Cutting Edge Processing Methods Affect Biological Properties of Amniotic Membrane Sheet Products
The FDA has taken enforcement action to underscore this distinction. In 2022 and 2024, warning letters were issued to companies marketing amniotic fluid-based eye products, on the grounds that these formulations are biological products requiring an investigational new drug application and approved licensing before they can be legally marketed. At least one product was voluntarily removed from the marketplace as a result.15PubMed Central. Cutting Edge Processing Methods Affect Biological Properties of Amniotic Membrane Sheet Products This does not mean the products are unsafe, but it means they have not undergone the rigorous clinical trial process the FDA requires for drug approval. If a clinic offers you “amniotic eye drops,” it is worth asking exactly what the product is, where it comes from, and whether it is derived from amniotic membrane (which has a clearer regulatory path as a tissue product) or amniotic fluid (which currently lacks FDA approval).
Cost and Access
Amniotic eye drops are not cheap. A cost-utility analysis comparing cryopreserved amniotic membrane plus topical medications against topical cyclosporine plus other medications for moderate-to-severe dry eye found that the amniotic membrane approach cost roughly $18,275 over one year, compared to about $20,740 for the cyclosporine-based regimen. But when looking at direct costs alone, cyclosporine was considerably less expensive at around $4,100 versus $10,300 for the amniotic membrane products.16PubMed Central. Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome The total cost calculation shifts when you factor in indirect costs like office visits and productivity, but the upfront expense of amniotic products remains a barrier for many patients, particularly because insurance coverage is inconsistent.
Some clinics prepare amniotic eye drops in-house through tissue banks, while others use commercially distributed products. Pricing varies widely. In some cases, doctors offer these drops as part of a broader treatment plan for severe ocular surface disease, where the cost is weighed against the alternative of repeated surgical interventions or continued vision loss.
What the Research Still Lacks
The biggest gap in the evidence is the absence of large, randomized controlled trials. Most of the clinical data comes from prospective case series, small cohort studies, and single-center trials, often with fewer than 40 patients. These studies consistently show positive results, but they are not the kind of rigorous, multi-center, placebo-controlled evidence that would satisfy regulators or settle debates about how amniotic drops compare to established treatments across large populations.
Standardization remains a genuine concern. Because the growth factor content of the final product depends on the donor tissue, the extraction method, and the processing conditions, two vials labeled “amniotic eye drops” can contain meaningfully different concentrations of the active components. Until manufacturing protocols are harmonized and products are characterized more rigorously, comparing results across studies is difficult, and patients cannot be sure that the product they receive will match the one used in the study their doctor cited.
Long-term data is also sparse. Most studies follow patients for weeks to a few months. Whether the benefits persist, whether repeated courses are needed, and whether any long-term risks emerge with chronic use are questions that remain open. The twelve-week follow-up from one dry eye trial showed sustained improvement, but that is still a relatively short window for a chronic condition.7PubMed Central. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
Amniotic Membrane Versus Amniotic Fluid Products
A source of confusion for patients is that “amniotic eye drops” can refer to products derived from two different biological sources. Amniotic membrane extract eye drops are made by processing the membrane itself, extracting its proteins and growth factors, and formulating the result as a topical drop. Amniotic fluid-based products use the liquid that surrounds the fetus during pregnancy, which also contains growth factors but in a different composition. Both have shown promise in early studies, but their regulatory status differs markedly in the U.S., as noted above. Amniotic fluid products currently face a harder path to legal marketing.
From a biological standpoint, the membrane extract tends to be richer in structural proteins like collagen and in certain growth factors associated with tissue repair, while amniotic fluid contains a broader mix of cytokines and other soluble factors. Whether one is clinically superior to the other for a given condition is not yet established. Researchers continue to refine extraction protocols for both sources, and the field is moving toward better characterization of what each product actually delivers to the eye.1PubMed Central. Amniotic membrane extract and eye drops: a review of literature and clinical application
How Amniotic Eye Drops Fit Into a Treatment Plan
If you are considering amniotic eye drops, the most important thing to understand is that they are typically positioned as a treatment for refractory disease, meaning conditions that have already failed first- and second-line therapies. Your ophthalmologist will likely have tried artificial tears, prescription anti-inflammatory drops, punctal plugs, and possibly autologous serum before turning to amniotic products. The drops are an addition to the treatment ladder, not a replacement for the earlier steps.
Dosing in clinical studies has generally involved applying drops several times daily for at least four weeks, though the exact regimen varies by product and condition. One preclinical protocol called for four applications per day spaced several hours apart.10PubMed Central. Clinically correlated dose of the amniotic membrane extract is superior to its transplantation in corneal wound healing Storage requirements depend on the formulation. Frozen products need to be kept cold and used quickly after thawing, while lyophilized versions can be reconstituted at room temperature before each use, which is more convenient for daily self-administration at home.
Patients who do respond tend to notice improvements in comfort before measurable changes in clinical signs, though the published data sometimes shows the reverse pattern, with objective measures improving more clearly than symptom scores. Either way, the response is rarely instantaneous. The biological repair processes the drops support take time, and patience through the first few weeks of treatment is generally necessary before either you or your doctor can judge whether they are working.